LCTX gets upgrade and is technically setup LONGLCTX on the weekly chart here has been falling since late 2021 and found support at the bottom
of the high volume area of the volume profile and ranged between it and the POC line for the
past 18 months. The is a high end clinically active biotechnology firm using stem cells to
produce therapeutic cell lines . ( One experiment using the mammary glands of cows imbedded
with cells that make insulin to make a weak milk solution containing insulin and then
concentrate it for cheap insulin is quite remarkable- ) How about some special milk for
to have with your sugar buzz) see more in the here link en.wikipedia.org
Anyway, price rose into triple confluence- the anchored mean VWAP, the POC line, the upper
boundary of the high volume area. A new analysis targets 7. Smart money is paying attention.
My smart money is paying a lot of attention. I understand the science and the market that
LCTX could reach in due time. I am not an insider but close. Enough said. My target is the
tweezer tops of 2022 at 2.5 and so 65-70% upside in the near to intermediate term and after
that maybe the analysis will revise the target up or down I am guessing the former.
LCTX trade ideas
$LCTX biotech company analysis *This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
My team has been following clinical-stage biotech company $LCTX for the past few months. $LCTX pipeline looks very promising. We believe that current price levels are undermining the companies potential. We entered $LCTX on 5/14/21 at $2.23 per share and have been holding ever since. Following its correction from its 52-week high of $3.13 $LCTX now sits at $2.80 per share.
My team averaged up on our $LCTX position this morning at $2.70 per share and intend to take profit at $4.20.
ORIGINAL ENTRY: $2.23
AVERAGING UP AT: $2.70
TAKE PROFIT: $4.20
STOP PROFIT LOSS: $2.50
If you want to see more, please like and follow us @SimplyShowMeTheMoney
LCTX-Short term long opportunity , AlphaOverBeta Price AlertLCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally.
The company has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Sector: Healthcare
Industry: Biotechnology
Market Cap(M$): 165
52 Week High: 1.67$
52 Week Low: 0.53$
Forward PE: -6.11
Analysts Recommendations
2015-12-22, Oppenheimer, Outperform
2016-02-19, Chardan Capital, Buy
2016-09-23, Ladenburg Thalmann, Buy
2019-03-18, Raymond James, Outperform
Technical Analysis:
Analyzing the stock from a technical perspective, we have these conclusions:
The stock is in an uptrend in the short-term and is expected to continue this trend for the next few days.
short-term momentum is positive and medium-term momentum looks positive based on technical momentum indicators for the perspective time periods.
Oversold/Overbought: the stock is overbought in the short term and is overbought in the medium term.
the recent trigger to buy/sell based on technical triggers is to buy.
Loading up on this one for the futureWhat's up fellow investors
We are currently loading up on LCTX , we expect this to be a 3$ stock before the summer considering the products + pipeline this company has to offer.
Do your own deep dive on this one !
Our average right now is 1.42 , we add on dips or momentum break ups.